Medicare Enrolled
Dr. Jagathi Challagalla, M.D.
Medical Oncology · Wichita Falls, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Challagalla from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Challagalla?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Challagalla
Dr. Jagathi Challagalla is a medical oncology specialist in Wichita Falls, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Challagalla performed 372,508 Medicare services across 9,387 unique beneficiaries.
Between the years covered by Open Payments, Dr. Challagalla received a total of $91,549 from 66 pharmaceutical and/or device companies across 343 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Challagalla is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in TX
$91,549 industry payments
Medicare Practice Summary
Medicare Utilization ↗372,508
Medicare services
Top 1% in TX for medical oncology
9,387
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~18,625 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 167,790 | $0 | $5 |
| Filgrastim injection (Nivestym) for white blood cells | 48,120 | $0 | $2 |
| Contrast dye for imaging (iodine-based) | 28,806 | $0 | $3 |
| Darbepoetin injection (Aranesp) for anemia | 23,800 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 23,500 | $43 | $137 |
| Oxaliplatin chemotherapy injection | 21,000 | $0 | $33 |
| Azacitidine chemotherapy injection | 13,698 | $0 | $13 |
| Iron sucrose injection (Venofer) | 11,200 | $0 | $2 |
| Blood draw (venipuncture) | 3,112 | $8 | $20 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,100 | $23 | $181 |
| Dexamethasone injection (steroid) | 2,928 | $0 | $1 |
| Complete blood count (CBC) with differential | 2,746 | $8 | $36 |
| Comprehensive metabolic blood panel | 2,665 | $10 | $64 |
| Denosumab injection (Prolia/Xgeva) | 1,620 | $16 | $67 |
| Office visit, established patient (20-29 min) | 1,485 | $62 | $250 |
| Injection, atropine sulfate, 0.01 mg | 1,360 | $0 | $1 |
| Injection, leucovorin calcium, per 50 mg | 1,189 | $3 | $25 |
| Injection, granisetron hydrochloride, 100 mcg | 1,150 | $0 | $24 |
| Injection, fluorouracil, 500 mg | 900 | $2 | $13 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 840 | $80 | $1,348 |
| Iron level test | 749 | $6 | $27 |
| Iron binding capacity test | 749 | $9 | $35 |
| Ferritin level test (iron stores) | 745 | $13 | $60 |
| Injection of additional new drug or substance into vein | 616 | $12 | $108 |
| Anti-nausea injection (Aloxi/palonosetron) | 570 | $1 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 503 | $98 | $707 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 486 | $46 | $313 |
| Carcinoembryonic antigen (cea) protein level | 336 | $19 | $99 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 328 | $3 | $373 |
| Drug injection, under skin or into muscle | 313 | $10 | $96 |
| Office visit, established patient (30-39 min) | 305 | $94 | $368 |
| Injection, zoledronic acid, 1 mg | 300 | $7 | $431 |
| Complete blood count (CBC), automated | 296 | $6 | $34 |
| Microscopic examination for white blood cells with manual cell count | 295 | $4 | $22 |
| Lactate dehydrogenase (enzyme) level | 280 | $6 | $31 |
| Ct scan of chest with contrast | 267 | $45 | $821 |
| CT scan of abdomen and pelvis with contrast | 244 | $169 | $1,067 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 233 | $22 | $157 |
| Injection, carboplatin, 50 mg | 220 | $2 | $300 |
| Administration of additional new drug or substance into vein, 1 hour or less | 179 | $49 | $344 |
| Administration of chemotherapy into vein, each additional hour | 177 | $21 | $161 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 175 | $55 | $211 |
| PSA test (prostate cancer screening) | 162 | $18 | $94 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 159 | $590 | $1,677 |
| Blood creatinine level | 158 | $5 | $31 |
| Irrigation of implanted venous access drug delivery device | 156 | $18 | $114 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 144 | $20 | $128 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 137 | $70 | $70 |
| Injection, diphenhydramine hcl, up to 50 mg | 135 | $1 | $7 |
| New patient office visit (30-44 min) | 124 | $75 | $372 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 118 | $341 | $1,722 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 116 | $1,101 | $4,802 |
| New patient office visit (45-59 min) | 110 | $119 | $565 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 109 | $90 | $657 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 108 | $272 | $2,762 |
| Administration of additional new drug or substance into vein using push technique | 101 | $42 | $289 |
| Injection, magnesium sulfate, per 500 mg | 96 | $1 | $6 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 94 | $123 | $500 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 91 | $25 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 88 | $15 | $94 |
| Unclassified drugs | 82 | $1 | $8 |
| Magnesium level test | 78 | $7 | $29 |
| Ct scan of soft tissue of neck with contrast | 70 | $48 | $658 |
| Infusion, normal saline solution , 1000 cc | 70 | $2 | $19 |
| Application of on-body injector for under skin injection | 69 | $14 | $96 |
| CT scan of chest, without contrast | 62 | $34 | $686 |
| Ct scan of abdomen and pelvis without contrast | 53 | $76 | $560 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 49 | $178 | $700 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 47 | $134 | $3,675 |
| Automated urinalysis | 42 | $2 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 40 | $16 | $100 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 40 | $1 | $19 |
| Red blood count, automated test | 33 | $4 | $23 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 32 | $4 | $25 |
| Infusion into a vein for hydration, 31-60 minutes | 29 | $25 | $256 |
| Drawing of blood for a medical problem | 29 | $70 | $264 |
| Infusion into a vein for hydration, each additional hour | 28 | $9 | $75 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | 27 | $177 | $700 |
| Vitamin B-12 level test | 19 | $15 | $76 |
| Nuclear medicine study whole body with ct scan | 16 | $1,104 | $4,929 |
| Ct scan of head or brain before and after contrast | 12 | $64 | $821 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
45.3% high complexity
50.4% medium
4.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$91,549
Total received (2018-2024)
Avg $13,078/year across 7 years
Top 16% in TX for medical oncology
66
Companies
343
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$70,453 (77.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$15,234 (16.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,862 (6.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$6,529
2023
$14,940
2022
$11,646
2021
$11,936
2020
$15,740
2019
$8,725
2018
$22,031
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$9,269
Gilead Sciences, Inc.
$9,003
Takeda Pharmaceuticals U.S.A., Inc.
$7,692
BeiGene USA, Inc.
$6,488
Celgene Corporation
$6,226
Janssen Biotech, Inc.
$5,859
Exelixis Inc.
$3,857
AstraZeneca Pharmaceuticals LP
$3,826
Bayer HealthCare Pharmaceuticals Inc.
$3,665
Karyopharm Therapeutics Inc.
$3,647
Fresenius Kabi USA, LLC
$3,175
Seagen Inc.
$3,126
GlaxoSmithKline, LLC.
$2,473
Amgen Inc.
$2,309
Seattle Genetics, Inc.
$2,128
Helsinn Therapeutics (U.S.), Inc.
$1,800
Rigel Pharmaceuticals, Inc.
$1,439
Kite Pharma, Inc.
$1,406
Daiichi Sankyo Inc.
$1,243
GENZYME CORPORATION
$1,200
Aveo Pharmaceuticals, Inc.
$1,050
CTI BioPharma Corp.
$1,018
BeiGene, Ltd.
$975
Novartis Pharmaceuticals Corporation
$947
Adaptive Biotechnologies Corporation
$846
Astellas Pharma US Inc
$794
Janssen Scientific Affairs, LLC
$758
Bayer Healthcare Pharmaceuticals Inc.
$656
EMD Serono, Inc.
$500
Lilly USA, LLC
$495
Pharmacyclics LLC, An AbbVie Company
$446
Incyte Corporation
$375
E.R. Squibb & Sons, L.L.C.
$370
PUMA BIOTECHNOLOGY, INC.
$256
Tempus AI, Inc
$163
Puma Biotechnology, Inc.
$155
Alexion Pharmaceuticals, Inc.
$150
Foundation Medicine, Inc.
$147
Pharmacosmos Therapeutics Inc.
$144
Taiho Oncology, Inc.
$141
Blueprint Medicines Corporation
$123
Clovis Oncology, Inc.
$121
Genentech USA, Inc.
$119
Verastem, Inc.
$117
Epizyme, Inc.,
$96
Merck Sharp & Dohme LLC
$95
Axonics, Inc.
$82
Eisai Inc.
$69
Apellis Pharmaceuticals, Inc.
$57
Regeneron Healthcare Solutions, Inc.
$56
ADC Therapeutics America, Inc.
$46
ABBVIE INC.
$38
Ipsen Biopharmaceuticals, Inc
$36
PharmaEssentia USA Corporation
$34
ImmunoGen, Inc.
$27
Acrotech Biopharma LLC
$24
Pharmacyclics LLC, an AbbVie Company
$23
Sun Pharmaceutical Industries Inc.
$23
Boehringer Ingelheim Pharmaceuticals, Inc.
$22
Acrotech Biopharma Inc.
$22
AbbVie Inc.
$20
Secura Bio, Inc.
$20
Sobi, Inc
$18
Stemline Therapeutics Inc.
$16
AVEO Pharmaceuticals, Inc.
$15
Kyowa Kirin, Inc.
$15
Top 3 companies account for 28.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · Aliqopa · Axonics · BELEODAQ · BESREMI · BOSULIF · BRUKINSA · CABLIVI · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DAURISMO · DOPTELET · ELIQUIS · ENHERTU · EPKINLY · ERLEADA · EXKIVITY · Elahere · Empaveli · Enhertu · FOTIVDA · Fabhalta · Farydak · GAVRETO · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · INREBIC · Imbruvica · JAKAFI · JEMPERLI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUTATHERA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nubeqa · OJJAARA · OPDIVO · Odomzo · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · Perjeta · Polivy · Pomalyst · Poteligeo · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SOMATULINE DEPOT · SUTENT · Stimufend · Stivarga · TABRECTA · TAGRISSO · TALZENNA · TAZVERIK · TRUSELTIQ · TUKYSA · Tavalisse · Tazverik · Tepmetko · Trodelvy · Ultomiris · VENCLEXTA · VERZENIO · Vanflyta · Vonjo · XPOVIO · XTANDI · Xofigo · Xtandi · Yescarta · ZEJULA · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (77%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $25 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
3
Per 100K population
34.3
County median income
$71,958
Nearest hospital
KELL WEST REGIONAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Challagalla is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with consulting-driven industry engagement in the top 16% of TX peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Challagalla experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Challagalla performed 167,790 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Challagalla receive payments from pharmaceutical companies?
Yes. Dr. Challagalla received a total of $91,549 from 66 companies across 343 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Challagalla's costs compare to other medical oncologists in Wichita Falls?
Dr. Challagalla's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Challagalla) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Wichita Falls
Browse medical oncologists in Wichita Falls ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology